Serum 25-hydroxyvitamin D levels and psychological distress symptoms in patients with affective disorders during the COVID-19 pandemic.
Depression
Hypovitaminosis D
Mood disorders
SARS-CoV-2
Stress response
Journal
Psychoneuroendocrinology
ISSN: 1873-3360
Titre abrégé: Psychoneuroendocrinology
Pays: England
ID NLM: 7612148
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
02
07
2020
revised:
10
09
2020
accepted:
10
09
2020
pubmed:
22
9
2020
medline:
15
12
2020
entrez:
21
9
2020
Statut:
ppublish
Résumé
The COVID-19 pandemic has given rise to stress worldwide, especially in vulnerable people like those suffering from mental illness. This study aims to investigate the psychological distress perceived by a cohort of patients with Major Depressive Disorder (MDD) or Bipolar Disorder (BD) after a seven-week period of lockdown measures, and to analyze serum 25-hydroxyvitamin D [25(OH)D] levels as a potential predictor of distress severity. Fifty-nine remitted MDD and fifty-three euthymic BD patients were enrolled. An online dedicated survey was administered to obtain lockdown-related information and to evaluate COVID-19 related distress by using the Kessler 10 Psychological Distress Scale (K10). Patients' medical records were reviewed to collect sociodemographic and clinical data, including serum 25(OH)D levels dosed in the three months preceding the outbreak. A multivariate general linear model was adopted to test the effect of factors of interest on psychological distress. In our sample (n = 112), 29 subjects (25.9 %) reported no likelihood of psychological distress, whereas 35 (31.2 %) and 48 (42.9 %) displayed mild and moderate-to-severe likelihood of psychological distress, respectively. Low serum 25(OH)D levels (p = 0.005) and MDD diagnosis (p = 0.001) specifically predicted the severity of psychological distress. Living alone during the lockdown, a longer duration of illness, and smoking habits were more frequently detected in subjects with COVID-19 related distress. Low serum 25(OH)D levels and MDD diagnosis predicted an increased vulnerability to the stressful impact of the COVID-19 outbreak. Our results suggest that vitamin D may represent a biological factor mediating the psychological response to stress in individuals with affective disorders and provide further insight into tailoring intervention strategies.
Sections du résumé
BACKGROUND
The COVID-19 pandemic has given rise to stress worldwide, especially in vulnerable people like those suffering from mental illness. This study aims to investigate the psychological distress perceived by a cohort of patients with Major Depressive Disorder (MDD) or Bipolar Disorder (BD) after a seven-week period of lockdown measures, and to analyze serum 25-hydroxyvitamin D [25(OH)D] levels as a potential predictor of distress severity.
METHODS
Fifty-nine remitted MDD and fifty-three euthymic BD patients were enrolled. An online dedicated survey was administered to obtain lockdown-related information and to evaluate COVID-19 related distress by using the Kessler 10 Psychological Distress Scale (K10). Patients' medical records were reviewed to collect sociodemographic and clinical data, including serum 25(OH)D levels dosed in the three months preceding the outbreak. A multivariate general linear model was adopted to test the effect of factors of interest on psychological distress.
RESULTS
In our sample (n = 112), 29 subjects (25.9 %) reported no likelihood of psychological distress, whereas 35 (31.2 %) and 48 (42.9 %) displayed mild and moderate-to-severe likelihood of psychological distress, respectively. Low serum 25(OH)D levels (p = 0.005) and MDD diagnosis (p = 0.001) specifically predicted the severity of psychological distress. Living alone during the lockdown, a longer duration of illness, and smoking habits were more frequently detected in subjects with COVID-19 related distress.
CONCLUSIONS
Low serum 25(OH)D levels and MDD diagnosis predicted an increased vulnerability to the stressful impact of the COVID-19 outbreak. Our results suggest that vitamin D may represent a biological factor mediating the psychological response to stress in individuals with affective disorders and provide further insight into tailoring intervention strategies.
Identifiants
pubmed: 32956989
pii: S0306-4530(20)30292-4
doi: 10.1016/j.psyneuen.2020.104869
pmc: PMC7489337
pii:
doi:
Substances chimiques
Vitamin D
1406-16-2
25-hydroxyvitamin D
A288AR3C9H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104869Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
Biol Psychiatry. 2008 Feb 15;63(4):398-405
pubmed: 17825799
Annu Rev Nutr. 2014;34:117-41
pubmed: 25033060
Aust N Z J Public Health. 2001 Dec;25(6):494-7
pubmed: 11824981
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Eur Psychiatry. 2020 Apr 01;63(1):e32
pubmed: 32234102
Schizophr Res. 2020 Sep;223:192-198
pubmed: 32771308
Br J Psychiatry. 2013 Feb;202:100-7
pubmed: 23377209
BMC Med. 2013 Sep 12;11:200
pubmed: 24228900
Psychoneuroendocrinology. 2013 Oct;38(10):2091-8
pubmed: 23608137
Nutrients. 2016 Oct 19;8(10):
pubmed: 27775565
Behav Brain Res. 2019 Jan 1;356:156-169
pubmed: 30144460
Brain Behav Immun. 2020 Jul;87:75-79
pubmed: 32325098
Brain Behav Immun. 2020 Oct;89:531-542
pubmed: 32485289
Lancet Psychiatry. 2020 Apr;7(4):e21
pubmed: 32199510
Psychiatry Clin Neurosci. 2020 Jun;74(6):372
pubmed: 32248608
Neurosci Biobehav Rev. 2019 Jun;101:13-31
pubmed: 30917923
Nutrients. 2020 Jun 30;12(7):
pubmed: 32629761
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jan 10;96:109760
pubmed: 31518608
Mol Psychiatry. 2014 Apr;19(4):444-51
pubmed: 23568194
J Clin Psychopharmacol. 2016 Dec;36(6):588-592
pubmed: 27662458
J Affect Disord. 2013 Feb 15;145(1):54-61
pubmed: 22921480
FASEB J. 2015 Jun;29(6):2207-22
pubmed: 25713056
Psychiatry Res. 2015 Sep 30;229(1-2):613-6
pubmed: 26027439
Psychol Med. 2020 Sep 08;:1-13
pubmed: 32895082
Biology (Basel). 2019 May 11;8(2):
pubmed: 31083546
Brain Behav Immun. 2020 Jul;87:100-106
pubmed: 32353518
Eur Psychiatry. 2015 Jun;30(4):441-7
pubmed: 25891263
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109651
pubmed: 31095994
JAMA. 2020 Aug 4;324(5):471-480
pubmed: 32749491
Eur Psychiatry. 2011 Mar;26(2):122-7
pubmed: 20620023
Psychoneuroendocrinology. 2017 Dec;86:53-63
pubmed: 28915381
J Affect Disord. 2017 Jan 15;208:56-61
pubmed: 27750060
Front Psychiatry. 2019 Mar 29;10:167
pubmed: 31001150
J Abnorm Psychol. 2011 Feb;120(1):142-54
pubmed: 21171724